Əsas səhifə

Çap

Əks əlaqə

İnfo
Plasma exchange for myasthenia gravis

Mündəricat

Plasma exchange for myasthenia gravis

Sübutlu məlumatların xülasələri
04.08.2017 • Sonuncu dəyişiklik 04.08.2017
Editors

Evidence is insufficient on the efficacy of plasma exchange to improve short- or long-term outcome for chronic myasthenia gravis or myasthenia gravis exacerbation.

A Cochrane review included 4 RCTs with 148 subjects with myasthenia gravis. In the first one on moderate or severe myasthenia gravis (MG, n=14) improvement after one month was not significantly greater for participants treated with plasma exchange and prednisone than for those treated with prednisone alone (95% CI -6.05 to 40.05). In the second one (n=12) comparing plasma exchange and iv. immunoglobulins (IVIg) with patients with moderate to severe MG, no significant difference was found in the efficacy of plasma exchange or IVIg after 4 weeks using a quantified myasthenia gravis score (QMGS). The third trial (n=87) with myasthenia gravis exacerbation found no significant difference between plasma exchange and IVIg after 2 weeks (95% CI: -5.72 to 7.72). However, very few patients with myasthenic crisis were included. The fourth study (n=35) showed a statistically significant difference in favour of plasma exchange before thymectomy in the duration of postoperative mechanical ventilation (1.3 vs. 1.7 hours, 95% CI - 2.12 to - 0.08) and the duration of ICU stay was 1.4 days vs. 1.9, 95% CI: - 2.30 to - 0.10).

Comment: The quality of evidence is downgraded by study quality (unclear allocation concealment), indirectness (very few patients with myasthenic crisis were included) and imprecise results (few patients and wide confidence intervals).

Ədəbiyyat

  1. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002;(4):CD002275. Review content assessed as up-to-date: 30 January 2011.